US 12,303,528 B2
Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
Thomas Michael Vaughn, Franklin, TN (US); Joshua Alan Harrison, Jonesborough, TN (US); Karl F. Popp, Schodack Landing, NY (US); David J. Fairfax, Slingerlands, NY (US); Thomas Edward D'Ambra, Big Torch Key, FL (US); and John Quinn, Troy, NY (US)
Assigned to ADORA ANIMAL HEALTH CORPORATION, Franklin, TN (US)
Filed by ADORA ANIMAL HEALTH CORPORATION, Franklin, TN (US)
Filed on Jun. 21, 2024, as Appl. No. 18/750,691.
Application 18/750,691 is a division of application No. 18/476,580, filed on Sep. 28, 2023, granted, now 12,059,430.
Claims priority of provisional application 63/411,363, filed on Sep. 29, 2022.
Prior Publication US 2024/0342208 A1, Oct. 17, 2024
Int. Cl. A61K 31/737 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 45/06 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01)
CPC A61K 31/737 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 45/06 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01)] 27 Claims
 
1. A pharmaceutical composition comprising:
a purified polysulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, wherein said purified polysulfated glycosaminoglycan includes no more than 10 wt % of carbohydrates or other contaminants with a molecular weight below 1,000 Daltons;
a skin penetrating agent, wherein said skin penetrating agent promotes transdermal penetration of said polysulfated glycosaminoglycan when applied to intact skin surfaces; and
a pharmaceutical carrier for topical application, said pharmaceutical carrier being mixed with said polysulfated glycosaminoglycan and said skin penetrating agent.